MET amplification has been observed in lung cancer patients treated with the EGFR inhibitors gefitinib and erlotinib, and treatment of gefitinib-resistant tumors with the Met inhibitor crizotinib is effective in the clinic for these patients [28]. The gene discussed is MET; the disease is lung carcinoma.